Yang, Bao-Zhu
Zhou, Hang
Cheng, Zhongshan
Kranzler, Henry R. http://orcid.org/0000-0002-1018-0450
Gelernter, Joel http://orcid.org/0000-0002-4067-1859
Funding for this research was provided by:
Philadelphia VA Medical Center Mental Illness Research, Education and Clinical Centers
Article History
Received: 20 March 2019
Accepted: 31 October 2019
First Online: 2 December 2019
Competing interests
: H.R.K. has been a consultant or advisory board member for Alkermes, Indivior, and Lundbeck, and he is a member of the American Society of Clinical Psychopharmacology Alcohol Clinical Trials Initiative, which was supported in the past 3 years by AbbVie, Alkermes, Ethypharm, Indivior, Eli Lilly, Lundbeck, Otsuka, Pfizer, Arbor Pharmaceuticals, and Amygdala Neurosciences. Drs Kranzler and Gelernter are named as inventors on PCT patent application #15/878,640 entitled: “Genotype-guided dosing of opioid agonists”, filed January 24, 2018.